Heterologous expression of lipoprotein-associated phospholipase A2 in different expression systems

Protein Expression and Purification

Volumn 48, Issue 2, 2006, Pages 300-306

  Zhang, Fujun ^a,b   Dong, Li ^a   Cai, Maojun ^a   Shen, Jingkang ^a   Wang, Yiping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Atherosclerosis; Baculovirus; Coronary; Expression; Insect cells; Lipoprotein associated phospholipase A2; Pichia pastoris; Purification

Indexed keywords

LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CYTOLOGY; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; INSECT; ISOLATION AND PURIFICATION; METABOLISM; PICHIA;

ANIMALS; ESCHERICHIA COLI; GENE EXPRESSION; INSECTS; LIPOPROTEINS, LDL; PHOSPHOLIPASES A; PICHIA; RECOMBINANT PROTEINS;

ESCHERICHIA COLI; INSECTA; PICHIA PASTORIS;

EID: 33746266941     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2006.03.009     Document Type: Article

References (28)

1. Zalewski A., and Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 923-931
2. Tjoelker L.W., Wilder C., Eberhardt C., et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374 (1995) 549-553
3. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338 (1999) 479-487
4. 2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett. 505 (2001) 357-363
5. Ballantyne C.M., Hoogeveen R.C., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
6. Oei H.H., van der Meer I.M., Hofman A., Koudstaal P.J., Stijnen T., Breteler M.M., and Witteman J.C. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111 (2005) 570-575
7. Koenig W., Khuseyinova N., Lowel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
8. Brilakis E.S., McConnell J.P., Lennon R.J., Elesber A.A., Meyer J.G., and Berger P.B. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur. Heart J. 26 (2005) 137-144
9. Iribarren C., Gross M.D., Darbinian J.A., et al. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 216-221
10. Dada N., Kim N.W., and Wolfert R.L. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev. Mol. Diagn. 2 (2002) 17-22
11. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343 (2000) 1148-1155
12. Macphee C.H. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr. Opin. Pharmacol. 1 (2001) 121-125
13. Macphee C., Benson G.M., Shi Y., and Zalewski A. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opin. Investig. Drugs 14 (2005) 671-679
14. Leach C.A., Hickey D.M., Ife R.J., Macphee C.H., Smith S.A., and Tew D.G. Lipoprotein-associated PLA2 inhibition-a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco. 56 (2001) 45-50
15. 2, synthesis and activity of analogues of sb-253514. Bioorg. Med. Chem. Lett. 10 (2000) 2015-2017
16. 2. Bioorg. Med. Chem. Lett. 11 (2001) 1925-1929
17. 2 for evaluation in man. Bioorg. Med. Chem. Lett. 12 (2002) 2603-2606
18. 2: 1-(biphenylmethylamidoalkyl)-pyrimidones. Bioorg. Med. Chem. Lett. 12 (2002) 51-55
19. 2. Bioorg. Med. Chem. Lett. 13 (2003) 1067-1070
20. Rotella D.P. SB-480848. GlaxoSmithKline. Curr. Opin. Investig. Drugs 5 (2004) 348-351
21. Tew D.G., Southan C., Rice S.Q.J., et al. Purification, properties, sequencing and cloning of a lipoprotein associated, serine dependent phospholipase which is involved in the oxidative modification of low density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 591-599
22. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
23. Pechan T., Ma P.W., and Luthe D.S. Heterologous expression of maize (Zea mays L.) Mir1 cysteine proteinase in eukaryotic and prokaryotic expression systems. Protein Expr. Purif. 34 (2004) 134-141
24. Rader D.J. Inflammatory markers of coronary risk. N. Engl. J. Med. 343 (2000) 1179-1182
25. 2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 3 (2002) 57-68
26. Macphee C.H., Nelson J.J., and Zalewski A. Lipoprotein-associated phospholipase A2 as a target of therapy. Curr. Opin. Lipidol. 16 (2005) 442-446
27. Kozak M. Downstream secondary structure facilitates recognition of initiator codons by eukaryotic. ribosomes. Proc. Natl. Acad. Sci. USA 87 (1990) 8301-8305
28. Kozak M. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 361 (2005) 13-37